sevuparin

Sevuparin is a chemically modified, low molecular weight heparin derivative with most of its anticoagulant activity removed while retaining potent anti-adhesive properties. It acts as a multimodal inhibitor of cell adhesion molecules, including P-selectin, L-selectin, E-selectin, fibronectin receptor, thrombospondin, and von Willebrand factor. Sevuparin blocks the adhesion of sickle red blood cells and leukocytes to endothelial cells and vascular cell adhesion molecule-1 (VCAM-1), thereby preventing vaso-occlusion in sickle cell disease (SCD). It is also being investigated as an adjunctive therapy for severe malaria by blocking Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1), which prevents merozoite invasion and cytoadherence. Sevuparin has orphan drug status for sickle cell anaemia and is under clinical development for vaso-occlusive crisis in SCD, falciparum malaria, anaemia, renal failure, and sepsis[1][3][6][8].

Other names

Low anticoagulant heparin